Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy · INZ-701

Phase 2Results posted Oct 27, 2026GlaxoSmithKlineNCT06104319

Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH

Non-alcoholic Fatty Liver Disease · GSK4532990

Phase 2Results posted Oct 26, 2026GlaxoSmithKlineNCT06663436

A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants

Diarrhoea · altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C

Phase 2Results posted Oct 22, 2026Recursion Pharmaceuticals Inc.NCT05085561

The Symptomatic Cerebral Cavernous Malformation Trial of REC-994

Cerebral Cavernous Malformation · REC-994, Placebo

Phase 2Results posted Oct 22, 2026Rapamycin Holdings Inc.NCT04230499

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

Familial Adenomatous Polyposis · Encapsulated Rapamycin (eRapa)

Phase 3Results posted Oct 22, 2026Merck Sharp & Dohme LLCNCT03036488

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms · Pembrolizumab, Carboplatin, Paclitaxel

Phase 1/Phase 2Results posted Oct 22, 2026TakedaNCT04420884

A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Solid Neoplasms · Dazostinag, Pembrolizumab, Platinum

Phase 2/Phase 3Results posted Oct 21, 2026Gilead SciencesNCT05502341

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

HIV-1-infection · Bictegravir, Lenacapavir, BIC/LEN FDC

Phase 2Results posted Oct 21, 2026Caliway Biopharmaceuticals Co., Ltd.NCT05632926

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

Cellulite · 40 mg CBL-514, 60 mg CBL-514, 80 mg CBL-514

Phase 3Results posted Oct 21, 2026Seagen, a wholly owned subsidiary of PfizerNCT04404283

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma · Brentuximab vedotin, Rituximab, Lenalidomide

Phase 1/Phase 2Results posted Oct 21, 2026Incyte Biosciences Japan GKNCT04661007

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma · tafasitamab, lenalidomide, parsaclisib

Phase 2Results posted Oct 21, 2026AbbVieNCT05105841

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) · Venetoclax, Ibrutinib, Obinutuzumab

Phase 2Results posted Oct 21, 2026Annexon, Inc.NCT04656561

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

Geographic Atrophy · ANX007

Phase 3Results posted Oct 20, 2026Janssen Research & Development, LLCNCT04630028

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Colitis, Ulcerative · Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo

Phase 3Results posted Oct 19, 2026Protagonist Therapeutics, Inc.NCT05210790

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

Polycythemia Vera · Rusfertide, Placebo

Phase 1/Phase 2Results posted Oct 19, 2026SanofiNCT06508489

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

Acute Myeloid Leukemia · SAR443579, venetoclax, azacitidine

Phase 1/Phase 2Results posted Oct 19, 2026EnteromeNCT05589597

EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Colorectal Cancer Metastatic · EO4010

Phase 2Results posted Oct 19, 2026Laekna LimitedNCT04374630

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Platinum-resistant Ovarian Cancer · Paclitaxel, Afuresertib

Phase 2Results posted Oct 19, 2026Allay Therapeutics, Inc.NCT06799845

Phase 2B Study Assessing Pain Relief After Replacement of the Knee

Total Knee Arthroplasty (Postoperative Pain) · ATX101, bupivacaine hydrochloride, saline placebo

Phase 2Results posted Oct 16, 2026Genentech, Inc.NCT05037929

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease · Astegolimab, Placebo

Phase 3Results posted Oct 16, 2026Eli Lilly and CompanyNCT06192108

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

Type 2 Diabetes · Orforglipron, Dapagliflozin

Phase 3Results posted Oct 16, 2026Eli Lilly and CompanyNCT06280716

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis · Placebo, Lebrikizumab, Topical Corticosteroid

Phase 2/Phase 3Results posted Oct 16, 2026Nektar TherapeuticsNCT05664217

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma · NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg

Phase 3Results posted Oct 15, 2026SanofiNCT04701983

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease · Itepekimab SAR440340, Placebo

Phase 3Results posted Oct 15, 2026Vertex Pharmaceuticals IncorporatedNCT05882357

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis · ELX/TEZ/IVA, IVA

Phase 3Results posted Oct 15, 2026United TherapeuticsNCT05255991

Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease · Placebo, Inhaled Treprostinil

Phase 3Results posted Oct 15, 2026ACADIA Pharmaceuticals Inc.NCT06173531

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Hyperphagia in Prader-Willi Syndrome · Carbetocin, Placebo

Phase 1/Phase 2Results posted Oct 14, 2026Bristol-Myers SquibbNCT05337137

A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer

Carcinoma, Hepatocellular · Relatlimab, Nivolumab, Bevacizumab

Phase 3Results posted Oct 14, 2026Ultragenyx Pharmaceutical IncNCT05139316

A Study of Adeno-Associated Virus Serotype 8-Mediated Gene Transfer of Glucose-6-Phosphatase in Patients With Glycogen Storage Disease Type Ia (GSDIa)

Glycogen Storage Disease Type IA · Oral prednisolone, Placebo for oral prednisolone

Phase 2Results posted Oct 14, 2026Ryan DackorNCT05617313

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer, Metastatic NSCLC, Recurrent Non Small Cell Lung Cancer · Pembrolizumab, GT103

Phase 2Results posted Oct 14, 2026Eidos Therapeutics, a BridgeBio companyNCT03536767

Open-Label Study of AG10 in Patients With Cardiomyopathy

Amyloid Cardiomyopathy · Acoramidis

Phase 3Results posted Oct 14, 2026Hoffmann-La RocheNCT05627557

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Childhood Idiopathic Nephrotic Syndrome · Obinutuzumab, MMF, Prednisone

Phase 2Results posted Oct 14, 2026Akaza Bioscience LtdNCT04620148

TAK-242 in Patients With Acute Alcoholic Hepatitis

Acute-On-Chronic Liver Failure · TAK-242, Placebo

Phase 2Results posted Oct 14, 2026Boehringer IngelheimNCT05512377

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer · Brigimadlin

Phase 3Results posted Oct 13, 2026Good Molecules, LLCNCT07136766

An 18-week Study to Evaluate a Test Product With a Marketed Prescription Product

Hyperpigmentation · Facial Toner

Phase 3Results posted Oct 13, 2026Lee's Pharmaceutical LimitedNCT04636957

Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis Externa

Acute Otitis Externa · Ciprofloxacin-Fluocinolone Acetonide, 0.3%-0.025% Otic Solution, Ciprofloxacin 0.3% solution

Phase 1/Phase 2Results posted Oct 13, 2026Sutro Biopharma, Inc.NCT06679582

Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML

Acute Myeloid Leukemia (AML) · Luveltamab tazevibulin

Phase 1/Phase 2Results posted Oct 13, 2026Inozyme PharmaNCT05030831

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE

ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum, Generalized Arterial Calcification of Infancy · INZ-701

Phase 3Results posted Oct 9, 2026Hoffmann-La RocheNCT03456063

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung · Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Placebo Comparator, Nab-paclitaxel

Phase 2Results posted Oct 9, 2026GlaxoSmithKlineNCT05412030

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal · AFX3772, Prevnar 13, Prevnar 20

Phase 3Results posted Oct 9, 2026SanofiNCT04751487

Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease · Itepekimab SAR440340, Placebo

Phase 3Results posted Oct 9, 2026Hoffmann-La RocheNCT03194893

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Neoplasms · Alectinib, Crizotinib

Phase 1/Phase 2Results posted Oct 9, 2026Karyopharm Therapeutics IncNCT04256707

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid Tumors · Selinexor 100 mg, Docetaxel, Pembrolizumab

Phase 2Results posted Oct 8, 2026Theriva Biologics SLNCT05673811

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma, Metastatic · Nab-paclitaxel, Gemcitabine

Phase 3Results posted Oct 8, 2026DBV TechnologiesNCT02916446

Safety Study of Viaskin Peanut to Treat Peanut Allergy

Peanut Allergy · Viaskin Peanut 250 µg, Placebo

Phase 3Results posted Oct 8, 2026BayerNCT05915702

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology · Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine

Phase 1/Phase 2Results posted Oct 8, 2026Grifols Therapeutics LLCNCT04722887

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency · Alpha-1 15%, Liquid Alpha1-Proteinase Inhibitor (Human)

Phase 3Results posted Oct 8, 2026PTC TherapeuticsNCT01247207

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

Duchenne Muscular Dystrophy · Ataluren

Phase 2Results posted Oct 8, 2026ModernaTX, Inc.NCT06508320

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Influenza, SARS-CoV-2 · mRNA-1083

Phase 2Results posted Oct 8, 2026Opus Genetics, IncNCT01703559

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss · Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%

Phase 2Results posted Oct 7, 2026Dr. Falk Pharma GmbHNCT05621811